Hot Features
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.1 | -21.4424951267 | 5.13 | 5.13 | 3.805 | 1241019 | 4.17278932 | DR |
| 4 | -1.37 | -25.3703703704 | 5.4 | 6.06 | 3.805 | 502595 | 4.61101388 | DR |
| 12 | -2.14 | -34.6839546191 | 6.17 | 6.31 | 3.805 | 400475 | 5.1498812 | DR |
| 26 | -0.15 | -3.58851674641 | 4.18 | 7.29 | 3.805 | 411455 | 5.55987195 | DR |
| 52 | 0.64 | 18.8790560472 | 3.39 | 7.9825 | 2.8536 | 271359 | 5.31128655 | DR |
| 156 | 0.03 | 0.75 | 4 | 7.9825 | 1.53 | 128754 | 4.70498616 | DR |
| 260 | -10.18 | -71.6396903589 | 14.21 | 16.93 | 1.53 | 86060 | 5.09595179 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.